Every year, thousands descend upon San Francisco from all over the world to hear the latest corporate updates from healthcare’s most important companies. The event, which is organized by J.P. Morgan, is often used to unveil market-moving news and this year’s conference was no disappointment:
Bristol-Myers Squibb (NYSE: BMY) announced a mega-deal for biotech Goliath Celgene (NASDAQ: CELG).
Eli Lilly (NYSE: LLY) acquired precision-cancer drug developer Loxo Oncology (NASDAQ: LOXO) for $8 billion.
And Sage Therapeutics (NASDAQ: SAGE) rolled out impressive data for a postpartum depression drug.
In this episode of The Motley Fool’s Industry Focus: Healthcare, Todd Campbell joins analyst Shannon Jones to explain why Bristol-Myers and Loxo Oncology are doing their deals and how Sage Therapeutics hopes to reshape how doctors treat depression. Tune in to learn if Celgene’s stock is still worth buying, Loxo Oncology can provide the spark Eli Lilly needs, and if Sage Therapeutics has a blockbuster drug on its hands.
Subscribe to The Motley Fool’s YouTube Channel:
Or, follow our Google+ page:
Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter: